Citi

Citi, a global financial services holding company, operates through two primary segments: Global Consumer Banking (GCB) and Institutional Clients Group (ICG). The GCB segment caters to retail customers, offering traditional banking services, Citi-branded cards, and retail services. The ICG segment serves corporate, institutional, and high-net-worth clients, providing a wide range of banking, financial, and investment services. Citi also manages approximately $4.3 billion in equity investments and committed capital through its global emerging markets private equity arm, CVCI. Additionally, Citi Ventures, the company's venture capital arm, invests in innovative ideas across sectors like fintech, data analytics, and digital assets, fostering growth and collaboration with Citi colleagues, clients, and the broader innovation ecosystem.

Avi Arnon

Senior Vice President

Krishna Balachanader

Managing Director

Thompson Barro

Senior Vice President, Venture Investing

Karine Ben-Simhon

VP Intelligence Partnerships and Innovation

Matt Carbonara

Managing Director, Venture Investing

Kateryna Chupryna

Director

Cagla Kaymaz

Senior Vice President

Everett Leonidas

Director

Robert Li

Vice President, Citi Ventures

Blaze O'Byrne

Vice President, Venture Investing

Vibhor Rastogi

Global Director, AI / ML / Data Investing at Citi Ventures

Meredith Shields

Managing Director

Ornit Shinar

Director and Head, Venture Investing

Cece Stewart

President

Kate Sullivan

COO

Avery Tiras

Equity Research Senior Associate

Luis Valdich

Managing Director, Venture Investing

Jelena Zec

Director

Past deals in Slovenia

Swixx Biopharma

Debt Financing in 2021
Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.